Exerkine Corporation is a biotech-pharmaceutical company that is developing highly effective new therapies to treat a variety of genetic and aging-associated diseases based on recent developments in the understanding of exercise physiology. Our passion for health and fitness are driving efforts to discover, develop and commercialize therapies that will ameliorate or cure many genetic diseases.
Key amongst these discoveries is Exerkine’s bioengineered exosome-based drug delivery technology, which shows great promise in the treatment of genetic diseases. Results from preclinical trials targeting disease groups, like Lysosomal Storage Diseases, have demonstrated improvements in health outcomes that significantly exceed the effectiveness of existing therapies approved by the FDA. Our exosome-based therapies have significant implications for a range of additional genetic maladies, such as mitochondrial myopathies and neuromuscular disorders.
In addition to our exosome-based technology, we have developed a number of therapies based on Exerkines™ that have the potential to treat aging-associated diseases, such as obesity, type 2 diabetes, cardiovascular diseases, and neurodegenerative diseases.
As we continue to development novel therapies, we will enter into partnerships that will accelerate the clinical testing and commercialization of our intellectual property and expand the potential of our treatment platform.
To improve the lives of patients by developing and commercializing novel and effective classes of therapies, cures, diagnostics.
To realize the vast potential of our exerkine and exosome-based technology by developing the broadest range of therapies, cures and diagnostics and maximizing the global reach and impact of our intellectual property.